🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Can FIB-4 then VCTE detect sig. fibrosis in MetALD? = Yes read Luis Antonio Díaz, MD paper MASLD Research Center Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver diseas… pubmed.ncbi.nlm.nih.gov/40377491/ AASLD Elliot Tapper

🧬New 📋 Veeral Ajmera Journal of Hepatology: In MASLD, inherited genetic risk drives age-associated fibrosis. ⬆️ LSMs after 40y in high-risk genotypes 🧪 PNPLA3 genotyping may improve risk stratification 📈 Supports personalized medicine 🔗 doi.org/10.1016/j.jhep… Rohit Loomba UCSD Gastroenterology

Thrilled to announce the release of the new American Diabetes Association - DiabetesPro Consensus Statement: #MASLD is now recognized as a major metabolic complication in type 2 diabetes and obesity, underscoring the central role of insulin resistance and cardiometabolic risk factors in its pathogenesis.

Thanks CGH for highlighting our decision algorithm to treat patients with #MASLD This international study was possible thanks to the collaboration of many people 🙏 Rohit Loomba Manuel Romero-Gómez Carmen Lara claraalf Salvador Benlloch Rocio aller Grupo de Investigación Biomédica en Imagen INCLIVA

Bringing genetic testing into the clinical management of people with MASLD: are we there yet? pubmed.ncbi.nlm.nih.gov/40449686/ Some reflections on recent advances in genetic testing implementation in hepatology! Journal of Hepatology

Our new paper on Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with MASH: a randomised, phase 2a trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa… Manuel Romero-Gómez Daniel Huang Naim Alkhouri Mazen Noureddin, MD, MHSc Quentin M. Anstee Christopher A. Longhurst, MD

New data Luis Antonio Díaz, MD MASLD Research Center on use of once monthly injectable naltrexone in patients with advanced ALD -Safety and Tolerability of Injectable Extended-Release Naltrexone for the Management of AUD in Adv… pubmed.ncbi.nlm.nih.gov/40515940/ AASLD

Original Article Head-to-head comparison of MASH resolution index versus FAST for non-invasive prediction of resolution of MASH on biopsy Loomba et al. Rohit Loomba #LiverX tinyurl.com/5n8477s6

HEPATOLOGY Journal Thanks HEPATOLOGY Journal for highlighting our paper on treatment response in MASH AASLD EASLnews Daniel Huang UCSD Gastroenterology Christopher A. Longhurst, MD Michael V. Drake Jorge Marrero Elliot Tapper Federica Tavaglione Mazen Noureddin, MD, MHSc Naim Alkhouri Quentin M. Anstee Manuel Romero-Gómez Ajay Duseja

📢Happening tomorrow! #LiverX, don’t miss the #EASLDeepDive on the 2024 #MASLD Clinical Practice Guidelines – live on 25 June, 18:00 CEST. ✅Diagnostic criteria ✅ Non-invasive tests for risk stratification ✅ #HCC risk & surveillance beyond #cirrhosis Register here:

Dr. Daniel Huang (Daniel Huang) joins #WCOG_AGW25! A transplant hepatologist, he brings immense expertise in #HCC, #MASLD and hepatitis B with 200+ papers & AGA guideline contributions. Catch him in Melbourne this September! 🔗 wgo-agw25.gesa.org.au

SYMMETRY trial: Efruxifermin was previously shown to reduce fibrosis in patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis. Research findings in patients with compensated cirrhosis are summarized in a new Quick Take video.

Nice editorial by Guadalupe GarciaTsao !

Thank you V Chen for inviting me! Genetic variants in PNPLA3, TM6SF2, MBOAT7 significantly linked to worse hepatic outcomes in #SLD. 📌 PNPLA3-GG → ↑ liver mortality (sHR 2.83) 📌 TM6SF2-T → ↑ HCC (sHR 2.12) 📌 MBOAT7-TT → ↑ MALO 🔗 doi.org/10.1111/apt.70…

JCI - Therapeutic horizons in metabolic dysfunction–associated steatohepatitis. Delighted to write this with ⁦Rohit Loomba⁩ ⁦King's College London⁩ ⁦The Roger Williams Institute of Liver Studies⁩ King's jci.org/articles/view/…

Great pleasure co-authoring this review with my good friend Phil Newsome JCI - Therapeutic horizons in metabolic dysfunction–associated steatohepatitis jci.org/articles/view/… AASLD ASCI EASLnews Christopher A. Longhurst, MD APASL News INASL

Go team ⁦UCSD Gastroenterology⁩ ! Terrific achievement and a brilliant team effort!!! ⁦MASLD Research Center⁩ ⁦Bernd Schnabl⁩ ⁦Veeral Ajmera⁩ ⁦Michael V. Drake⁩ ⁦Christopher A. Longhurst, MD⁩ ⁦EASLnews⁩ ⁦INASL⁩ ⁦⁩ ⁦Grace Su⁩ ⁦San Diego Digestive Diseases Research Center⁩